Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Urethral Morphology and Support Associated with Urinary Symptoms after Vaginal Surgery with and without Midurethral Sling.
Journal: medRxiv : the preprint server for health sciences
Published: June 04, 2026
Patient Autonomy and Control Preferences in Prolapse Treatment Decision Making.
Journal: Urogynecology (Philadelphia, Pa.)
Published: June 01, 2025
Prolapse Treatment-Related Decisional Conflict After New Patient Visits.
Journal: Urogynecology (Philadelphia, Pa.)
Published: September 27, 2024
Randomized Trial on Expectations and Pain Control Advancement in Surgery: The REPAIR Study.
Journal: Urogynecology (Philadelphia, Pa.)
Published: July 10, 2023
Risk Factors for De Novo Overactive Bladder After Midurethral Sling.
Journal: Urogynecology (Philadelphia, Pa.)
Published: June 16, 2023
Factors Associated With Increased Estimated Blood Loss and Factors Associated With Utilization of Type and Screen in Benign Gynecology: A Retrospective Chart Review.
Journal: Urogynecology (Philadelphia, Pa.)
Published: February 03, 2023
Female Pelvic Fistulae.
Journal: Obstetrics and gynecology clinics of North America
Published: August 21, 2021
A lasting impression: telemedicine in urogynecology during the coronavirus disease 2019 pandemic.
Journal: Current opinion in obstetrics & gynecology
Published: September 05, 2020
Erratum to "Evaluation of clear cell subtypes of ovarian and uterine malignancies with anti-PD-L1 and anti-PD1 immunohistochemical expression and their association with stage and survival" [Gynecol. Oncol. 155 (2019) 483-488].
Journal: Gynecologic oncology
Published: February 16, 2020
A ruptured vulvar labial artery pseudoaneurysm causes a secondary postpartum hemorrhage: A case report.
Journal: Case reports in women's health
Published: February 11, 2020
Evaluation of clear cell subtypes of ovarian and uterine malignancies with anti-PD-L1 and anti-PD1 immunohistochemical expression and their association with stage and survival.
Journal: Gynecologic oncology
Published: July 04, 2019
The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab.
Journal: Recent patents on biotechnology
Published: May 22, 2017
Last Updated: 09/26/2026